Close

Novo Nordisk increased operating profit by 27% in 2010

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CDMO Market For Small Molecule Innovation Soars By 2033

It has been anticipated that the market for contract...

API Sourcing Redefining Global Pharmaceutical Supply Chain

The COVID-19 pandemic went on to expose crucial susceptibility...

Pharmaceutical Fine Chemicals Market to hit $235bn by 2030

The pharmaceutical fine chemicals market is all set for...

The Overall Spectrum Study of the Global HPAPI Market

High-potency active pharmaceutical ingredients - HPAPIs happen to represent...

Organic sales growth of 19% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 19% in Danish kroner and by 13% in local currencies. Gross margin improved by 1.2 percentage points in Danish kroner to 80.8% in 2010, reflecting a favourable product mix development and a positive currency impact. Reported operating profit increased by 27% to DKK 18,891 million. Measured in local currencies, operating profit increased by approximately 16%. Net profit increased by 34% to DKK 14,403 million. Earnings per share (diluted) increased by 38% to DKK 24.60.

The phase 3a programme for Degludec and DegludecPlus has now been completed. In the largest trial, the one-year trial comparing Degludec and insulin glargine when added to oral anti-diabetic therapy in type 2 diabetes, Degludec met the primary endpoint of non-inferior glucose control while reducing nocturnal hypoglycaemia by more than 35% compared to insulin glargine.

For 2011, sales growth measured in local currencies is expected to be 8-10%, and operating profit growth measured in local currencies is expected to be around 15%.

In 2010, Novo Nordisk reached the four long-term financial targets announced in the annual report for 2008. Consequently, three of the four targets have been increased while the core target of 15% annual operating profit growth has been maintained.

At the Annual General Meeting on 23 March 2011, the Board of Directors will propose a 33% increase in dividend to DKK 10 per share. The Board of Directors has furthermore decided to initiate a new share repurchase programme of DKK 10 billion in 2011.

Lars Rebien Sørensen, president and CEO: “2010 was a very good year for Novo Nordisk with strong organic sales growth driven by the modern insulins and Victoza®. We expect continued sales growth from these products and are encouraged by the results from the phase 3 programme with our new generation insulins.”

Latest stories

Related stories

CDMO Market For Small Molecule Innovation Soars By 2033

It has been anticipated that the market for contract...

API Sourcing Redefining Global Pharmaceutical Supply Chain

The COVID-19 pandemic went on to expose crucial susceptibility...

Pharmaceutical Fine Chemicals Market to hit $235bn by 2030

The pharmaceutical fine chemicals market is all set for...

The Overall Spectrum Study of the Global HPAPI Market

High-potency active pharmaceutical ingredients - HPAPIs happen to represent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back